Clinical trial
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)
NCT05461170 is registered in ClinicalTrials.gov with Vir Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)
- Lead sponsor
- Vir Biotechnology, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 17, 2022
- Completion date
- May 31, 2032
- Enrollment
- 95 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.